Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

Part of paid clinical trials in West Lafayette, Indiana.

Sponsor
Corvus Pharmaceuticals, Inc.
Study ID
NCT07828860
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa

Key Dates

First listed
Sep 18, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Single-Arm
    Participants receive open-label single arm of active tablets orally twice daily for 84 days.

Primary Outcome Measure

Incidence of adverse events, changes in laboratory values, vital signs, and ECGs [ Time Frame: up to 30 days after last intervention administration ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
Clinical Site 9West LafayetteIndiana47906-
Clinical Site 1Bowling GreenKentucky42104-
Clinical Site 2OwensboroKentucky42303-
Clinical Site 3BostonMassachusetts02215-
Clinical Site 5New YorkNew York10023-
Clinical Site 4The BronxNew York10455-
Clinical Site 11FargoNorth Dakota58103-
Clinical Site 10Mayfield HeightsOhio44124-
Clinical Site 6Camp HillPennsylvania17011-
Clinical Site 8PhiladelphiaPennsylvania19103-
Clinical Site 7NashvilleTennessee37211-

Find similar trials in West Lafayette, IN

Related Studies